This meta-analysis evaluated the cardiovascular safety profile of osimertinib in a large cohort of 10,316 patients diagnosed with EGFR-mutated non-small cell lung cancer (NSCLC). The study specifically focused on identifying and quantifying various cardiovascular adverse events (CVAEs) to inform clinical management for patients undergoing targeted therapy.
The primary outcomes measured included all grades and grade \u2265 3 QTc prolongation, left ventricular ejection fraction (LVEF) decrease, 3-point major adverse cardiovascular events (MACE), venous thromboembolism (VTE), and hypertension. These metrics were used to compare osimertinib against other treatment regimens, including anti-VEGF combination therapies and platinum-pemetrexed combinations.
Regarding the primary outcomes, hypertension was identified as the most common treatment-emergent and treatment-related CVAE for patients receiving osimertinib. For QTc prolongation (all grades), the study reported a rate of 6.88% (95% CI 5.24%-8.70%). In contrast, when osimertinib was combined with platinum-pemetrexed, the incidence of QTc prolongation increased significantly to 22.24%. Similarly, LVEF decrease (all grade) was reported at 4.31% (95% CI 2.38%-6.69%) for standard osimertinib use, but rose to 6.53% (or 15.82% in alternative reporting) when combined with platinum-pemetrexed.
Secondary outcomes included the assessment of treatment-emergent and treatment-related CVAEs. A notable finding was the higher incidence of hypertension in anti-VEGf combination therapy, where treatment-emergent cases reached 45.46% compared to 26.11% for treatment-related cases. The data suggests that while osimertinib is associated with cardiovascular risks, certain combinations—specifically those involving anti-VEGF agents—exhibit a more severe cardiac safety profile.
Safety and tolerability findings indicate that hypertension is the most frequent CVAE associated with osimertinib. The study noted that these cardiovascular toxicities were specifically related to the treatment regimens used rather than being influenced by patient demographics such as age, race, or prior exposure to EGFR-TKIs. This suggests that the choice of combination therapy is a critical factor in determining the risk profile for cardiac complications.
When compared to historical data in this therapeutic area, these results highlight the specific risks associated with combining targeted therapies with other agents. The higher rates of QTc prolongation and LVEF reduction in the platinum-pemetrexed combination suggest that multi-agent regimens may increase cardiovascular burden. However, the study does not provide a direct comparison to older standard-of-care chemotherapies.
Methodological limitations include the lack of reported data regarding specific study settings, follow-up durations, and detailed counts for serious adverse events or treatment discontinuations. Additionally, the absence of reported confidence intervals for several secondary outcomes limits the precision of some findings. These gaps necessitate a cautious interpretation of the absolute risk for less common CVAEs like MACE and VTE.
Clinical implications suggest that while osimertinib is a standard of care for EGFR-mutated NSCLC, clinicians must remain vigilant regarding hypertension as the most frequent CVAE. Furthermore, patients receiving anti-VEGF combinations or platinum-pemetrexed combinations may require more intensive cardiovascular monitoring due to higher rates of QTc prolongation and LVEF reduction. These findings allow for a more nuanced risk assessment when selecting combination therapies.
Several questions remain unanswered regarding the long-term impact of these CVAEs on patient quality of life and survival. Additionally, the specific mechanisms driving the increased cardiac toxicity in platinum-pemetrexed combinations versus standard osimertinib monotherapy require further investigation to optimize safety protocols.
How this fits prior evidence
How this fits prior evidence
This meta-analysis provides new data regarding cardiovascular safety in EGFR-mutated NSCLC. While previous reports focused on outcomes like the 58.5% objective response rate for ALK tyrosine kinase inhibitors or the benefits of sacituzumab tirumotecam combined with pembrolizumab, this study specifically addresses the CVAE profile of osimertinib. It identifies hypertension as a primary concern and highlights that anti-VEGF combinations have a more severe cardiac safety profile than standard osimertinib.
